(AOF) – Aelis Farma announces cash flow of 20.2 million euros as of December 31, 2023, confirming its financial visibility until the end of 2025. The biotech specializing in the development of treatments for brain diseases posts a net loss of 5.07 million euros compared to 14.28 million in 2022. Aelis Farma plans to announce the effectiveness results of the phase 2b study with AEF0117 after the summer of 2024. At the end of these results, the Indivior group could exercise its license option triggering the payment of a license fee of $100 million.
Aelis Farma has signed a licensing contract with Indivior, “leader in addiction treatment”.
The biotech envisages up to 340 million additional payments, conditional on the achievement of development, regulatory and commercial milestones, as well as royalties on net sales of AEF0117 of between 12% and 20%.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.